{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"C4-MOSART","nct_id":"NCT03431948","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=c4-mosart-nct03431948. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"C4-MOSART","arms":[{"description":"Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.","label":"SBRT with Nivolumab and Urelumab","type":"EXPERIMENTAL"},{"description":"Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .","label":"SBRT with Nivolumab and Cabiralizumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2022-04-11","type":"ACTUAL"},"conditions":["Cancer"],"enrollment":{"count":60,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["OPDIVO","BMS-936558"],"type":"DRUG"},{"name":"Cabiralizumab","otherNames":["BMS-986227","FPA008"],"type":"DRUG"},{"name":"Urelumab","otherNames":["BMS-663513"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy","otherNames":[],"type":"RADIATION"}],"last_update":"2023-02-16","lead_sponsor":"University of Chicago","official_title":"Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2020-02-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Recommended dose of SBRT given in combination with immunotherapy","timeFrame":"3 months"}],"references":[],"start_date":{"date":"2018-03-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer","url":"https://clinicaltrials.gov/study/NCT03431948"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/c4-mosart-nct03431948"}